Emerging technologies to increase ligand binding assay sensitivity - Wikidata - awgldk - TriplyDB

Emerging technologies to increase ligand binding assay sensitivity

Emerging technologies to increase ligand binding assay sensitivity

http://www.wikidata.org/entity/Q34871754

about

Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.HIV-1 latent reservoir: size matters Ultrasensitive bioanalysis: current status and future trends.Application of multiplex immunoassay technology to investigations of ocular disease.Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.Selecting analytical biomarkers for diagnostic applications: a first principles approach.Development of a plug and play ImmunoPCR technique for the analysis of biomolecules.3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis.Platform switching from ELISA to Gyrolab™: a novel generic reagent omits the need to change critical reagents.First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.Bioanalytical challenges and improved detection of circulating levels of IL-13.

P2860

Q26770708-80FDC69F-DA1A-4D91-B4FB-3602B0DFC77F Q30391340-F4505CD8-9231-4D76-84A4-736AC79FCCD6 Q34486159-2E3A6CB4-6840-489F-A5FD-C323453CE830 Q38649553-98A13A37-14B1-41B2-AE69-669EBE7F725B Q38685682-4301DE21-7612-4294-A7A9-4D5E838FF29C Q38941639-9D302CFA-0A5E-4528-BAC6-F13D61ED329D Q47225640-70300669-09D9-44FF-9A12-AB83448D5E08 Q48265538-D23DFDFE-BC56-4AA9-BF71-E381DC332750 Q50098404-D5F471BB-6915-47C6-A5B5-D7CD007FE2CE Q50123752-749D0061-2439-4AD9-8D95-B08D8C4F5AB6 Q51181142-1CBC7854-B6C4-44BD-BE79-5CB58B74EED9 Q51445222-3C231E6D-5905-46FA-8EB5-A89976B7E3AE Q52645845-19A95718-76CD-4A6D-9A6F-2E5DF1543AD9 Q53186302-B059D8DE-C6C0-4D8E-BC68-C2F519DB3192

P2860

Emerging technologies to increase ligand binding assay sensitivity

http://www.wikidata.org/entity/Q34871754

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Emerging technologies to increase ligand binding assay sensitivity

@ast

Emerging technologies to increase ligand binding assay sensitivity

@en

Emerging technologies to increase ligand binding assay sensitivity

@nl

type

label

Emerging technologies to increase ligand binding assay sensitivity

@ast

Emerging technologies to increase ligand binding assay sensitivity

@en

Emerging technologies to increase ligand binding assay sensitivity

@nl

prefLabel

Emerging technologies to increase ligand binding assay sensitivity

@ast

Emerging technologies to increase ligand binding assay sensitivity

@en

Emerging technologies to increase ligand binding assay sensitivity

@nl

P1433

Q34871754-EDDE3456-B982-4886-9AD4-6C08B7A28703

P1476

Q34871754-CE5467E4-D13F-4AFE-B4AD-C44621EACA44

P2093

Q34871754-29B46C93-44E3-4E72-A05A-62E3DE761B9D

Q34871754-4407CF24-1600-4EA5-92FC-E8FCD4A128B7

Q34871754-583EA95B-7322-4B06-B846-0B77A53495DF

Q34871754-67AD4299-E037-43C1-8D36-B6E454CAB294

Q34871754-6C3693B4-69AF-4524-8AA7-215B4C979861

Q34871754-CAA66C2D-5475-42E2-AE88-76EBC4AB5FFC

Q34871754-CD21CA90-AC89-4FA7-B445-82139FB92B3E

P2860

Q34871754-021D873A-8C3F-4823-9FEA-EDF90740458B

Q34871754-05ADD0E0-6AF4-4897-9895-5B02628DEB5E

Q34871754-16624BD3-675A-4EDE-8B90-2258017F0375

Q34871754-24C61CC9-73ED-4DA5-AC77-410D40E8442C

Q34871754-2E9F4D92-FD53-4D9C-AB9E-C78047A15ED7

Q34871754-3C1B1CC7-8FD8-4B40-9306-BB2DC83A6E0D

Q34871754-4031E03C-AD9D-4F6D-9B37-9BD9797CBEA1

Q34871754-467FF697-8D1B-49C5-88A8-4A0551D6AB82

Q34871754-4EA31DA0-853A-4225-99CC-196178162C05

Q34871754-4F732317-7FA0-4D7A-B496-770081D6ACDD

P2888

Q34871754-84EECCEB-F3AD-41D3-9C2A-97B64A94D50F

P304

Q34871754-FB6002AD-A5FB-4545-9273-869FA02B02B9

P31

Q34871754-DA2400EA-EDA5-4336-A2A5-78A46C2EFDC7

P356

Q34871754-8CC660E0-C351-4D12-9AA9-C066DD23EABD

P407

Q34871754-80969959-4DBE-4B41-B9CF-832C9FD65B51

P433

Q34871754-8AB44501-9143-46DC-82DA-1EBB91E0F47C

P478

Q34871754-2EDFF617-1613-47A0-ACCB-3CD919CB851E

P577

Q34871754-063C212B-4C38-4CDE-92B1-2186BC81BDAA

P5875

Q34871754-300C8C37-C4C1-4B15-BAE0-96AF9CC348CA

P6179

Q34871754-32A09480-DCFD-4CB8-83D6-3D993E375340

P698

Q34871754-B123C2B5-7907-4EDC-BEC1-A42FE96D0C56

P921

Q34871754-04630FA2-B9D5-4F0C-8F60-CB987E90E377

P932

Q34871754-18BBBAE1-E28A-4B3A-97C8-0931E3922F98

P356

S12248-014-9682-8

P1433

The AAPS Journal

P1476

Emerging technologies to increase ligand binding assay sensitivity

@en

P2093

Alison Joyce

http://www.w3.org/2001/XMLSchema#string

Alvydas Mikulskis

http://www.w3.org/2001/XMLSchema#string

Marianne Scheel Fjording

http://www.w3.org/2001/XMLSchema#string

Mark Spengler

http://www.w3.org/2001/XMLSchema#string

Saloumeh K Fischer

http://www.w3.org/2001/XMLSchema#string

Tong-Yuan Yang

http://www.w3.org/2001/XMLSchema#string

Yao Zhuang

http://www.w3.org/2001/XMLSchema#string

P2860

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

A simpler, more sensitive competitive inhibition enzyme-linked immunosorbent assay for detection of antibody to malignant catarrhal fever viruses.

Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates.

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.

Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range.

P2888

s12248-014-9682-8

P304

93-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-014-9682-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267272895

http://www.w3.org/2001/XMLSchema#string

P6179

1019872776

http://www.w3.org/2001/XMLSchema#string

P698

25331105

http://www.w3.org/2001/XMLSchema#string

P921

P932

4287293

http://www.w3.org/2001/XMLSchema#string